

## TIE2 CD202b Antibody FITC Conjugated

Catalog No: #C02254F

Orders: [order@signalwayantibody.com](mailto:order@signalwayantibody.com)Support: [tech@signalwayantibody.com](mailto:tech@signalwayantibody.com)

## Description

Product Name	TIE2 CD202b Antibody FITC Conjugated
Host Species	Rabbit
Clonality	Polyclonal
Isotype	IgG
Purification	Purified by Protein A.
Applications	Flow-Cyt IF
Species Reactivity	Hu Ms Rt
Immunogen Description	KLH conjugated synthetic peptide aa 450-500 1124 derived from human Tie2
Conjugates	FITC
Target Name	TIE2 CD202b
Other Names	TIE2; VMCM; TIE-2; VMCM1; CD22B; Angiopoietin-1 receptor; Endothelial tyrosine kinase; Tunica interna endothelial cell kinase; Tyrosine kinase with Ig and EGF homology domains-2; Tyrosine-protein kinase receptor TEK; Tyrosine-protein kinase receptor TIE-2; hTIE2; p14 TEK; TEK
Accession No.	Swiss-Prot#Q02763NCBI Gene ID7010
Uniprot	Q02763
GeneID	7010;
Excitation Emission	494nm 518nm
Cell Localization	Extracellular
Concentration	1mg ml
Formulation	0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage	Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

## Application Details

Flow-Cyt=1:50-200 IF=1:50-200

## Background

Tyrosine-protein kinase that acts as cell-surface receptor for ANGPT1, ANGPT2 and ANGPT4 and regulates angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton, but also maintenance of vascular quiescence. Has anti-inflammatory effects by preventing the leakage of proinflammatory plasma proteins and leukocytes from blood vessels. Required for normal angiogenesis and heart development during embryogenesis. Required for post-natal hematopoiesis. After birth, activates or inhibits angiogenesis, depending on the context. Inhibits angiogenesis and promotes vascular stability in quiescent vessels, where endothelial cells have tight contacts. In quiescent vessels, ANGPT1 oligomers recruit TEK to cell-cell contacts, forming complexes with TEK molecules from adjoining cells, and this leads to preferential activation of phosphatidylinositol 3-kinase and the AKT1 signaling cascades. In migrating endothelial cells that lack cell-cell adhesions, ANG1 recruits TEK to contacts with the extracellular matrix, leading to the formation of focal adhesion complexes, activation of PTK2 FAK and of the downstream kinases MAPK1 ERK2 and MAPK3 ERK1, and ultimately to the stimulation of sprouting angiogenesis. ANGPT1 signaling triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Signaling is modulated by ANGPT2 that has lower affinity for TEK, can promote TEK autophosphorylation in the absence of ANGPT1, but inhibits ANGPT1-mediated signaling by competing for the same binding site. Signaling is also modulated by formation of heterodimers with TIE1, and by proteolytic processing that gives rise to a soluble TEK extracellular domain. The soluble extracellular domain modulates signaling by functioning as

decoy receptor for angiopoietins. TEK phosphorylates DOK2, GRB7, GRB14, PIK3R1; SHC1 and TIE1.

---

Note: This product is for in vitro research use only